GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Ozempic gains expanded approval; Boxed Warning added to MS treatment label; Monotherapy approval granted to Spravato; Leqembi gains maintenance regimen; Enhertu gains new breast cancer indication.

According to the prescribing information, patients treated with Spravato should receive a dose twice a week for the first four weeks. In the following four weeks, the dosing is reduced to once per ...

Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal spray Spravato as the first stand-alone therapy for adults with treatment-resistant depression. The Food and Drug Administration’s ...

Many of these drugs, however, come with unwanted side effects, like hallucinations or disconnection from the self, which makes practical dosing difficult. After a spray of Spravato, patients often ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

The nasal spray called Spravato is being manufactured by Johnson & Johnson's and has been approved as a standalone treatment for major depressive disorder (MDD). MDD is one of the most common ...